Functional Service Provider (FSP) Model

Building trust and long-term strategic global partnerships

You did an amazing job in such a short time. Thank you very much for your partnership!
Program Lead
Global Pharmaceutical Sponsor

At MMS, our customer-aligned FSP teams go beyond delivery. We partner with you to find the right outsourcing model, level of oversight, scale, and governance to provide a functional sourcing solution that best suits your organization’s unique needs.

Sponsors around the globe engage with MMS as a CRO provider for FSP partnerships in the following areas:

Our FSP models are designed to be flexible and scalable, allowing MMS experts a level of engagement to adapt to your changing needs. Tailored key performance indicators (KPI), governance, and communication plans meet you where you are, as well as provide the tools and structure to achieve your long- and short-term strategic goals.

As an innovative, award-winning CRO, MMS leverages decades of evolving, long-term FSP partnerships with a commitment to process improvement, cost efficiencies, and innovation to help you succeed.

Key benefits of choosing the MMS FSP model include:

  • Experience and consistency of an FSP relationship allows MMS to bring the greatest value and specialized knowledge, rather than other transactional models
  • Effective and efficient communication plans by defining roles and responsibilities, with a clear escalation process
  • Access to global talent ensures seamless resourcing strategies and ability to meet urgent timelines due to regulatory and/or team needs
  • With a focus on innovation and technology, MMS can bring our combined service and technology solutions to build efficient processes and bring time and effort savings
  • Operational efficiencies are gained through interdependent cross-functional services in medical writing, data services, pharmacovigilance, quality control and more
  • Through value-added FSP partnerships, MMS strives for seamless collaborations that build trust

Request more information on our suite of customizable FSP solutions.

Suggested For You

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar